|1.||Jones, Barry: 5 articles (08/2011 - 09/2003)|
|2.||Aziz, Nazneen: 2 articles (08/2011 - 06/2009)|
|3.||Nemunaitis, John: 2 articles (01/2009 - 10/2006)|
|4.||Watanabe, Takeshi: 2 articles (08/2004 - 09/2003)|
|5.||Jesson, Michael I: 2 articles (08/2004 - 09/2003)|
|6.||Miller, Glenn T: 2 articles (08/2004 - 09/2003)|
|7.||Wallner, Barbara P: 2 articles (08/2004 - 09/2003)|
|8.||Adams, Sharlene: 2 articles (08/2004 - 09/2003)|
|9.||Campins, Magda: 1 article (11/2014)|
|10.||Balfagón, Pilar: 1 article (11/2014)|
10/01/2006 - "Five of 7 patients receiving 800 microg on Days 2-8 experienced a >/=1-day improvement in Grade 3+ neutropenia in Cycle 2 versus Cycle 1. Overall, PT-100 was well tolerated. "
10/01/2006 - "Patients had to develop Grade 3+ neutropenia in Cycle 1 in order to receive PT-100 in Cycle 2. Most patients received PT-100 on Days 2-8 of chemotherapy in Cycle 2, except at 800 microg where an additional cohort (n = 8) was treated on a Days 5-11 schedule. "
09/01/2003 - "PT-100 is a therapeutic candidate for the treatment of neutropenia and anemia. "
06/16/2010 - "An adaptive phase I trial design incorporating maximum target inhibition as the primary endpoint was developed to define the optimal dose of talabostat, a dipeptidyl peptidase (DPP) inhibitor, in children with relapsed or refractory solid tumors. "
08/01/2004 - "PT-100 has no direct cytotoxic effect on tumors in vitro. "
08/01/2004 - "Because fibroblast activation protein is also expressed in stroma of lymphoid tissue and tumors, the effect of PT-100 on tumor growth was studied in mice in vivo. "
10/01/2006 - "Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy."
08/01/2004 - "In WEHI 164 fibrosarcoma and EL4 and A20/2J lymphoma models, PT-100 caused regression and rejection of tumors. "
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|4.||Melanoma (Melanoma, Malignant)
09/01/2007 - "In clinical trials, talabostat has demonstrated significant activity, including achieving complete responses in patients with non-small-cell lung cancer and malignant melanoma."
01/01/2009 - "Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma."
08/01/2004 - "Oral administration of PT-100 to mice slowed growth of syngeneic tumors derived from fibrosarcoma, lymphoma, melanoma, and mastocytoma cell lines. "
12/01/2006 - "This issue focuses on the following selection of drugs: 5-Methyltetrahydrofolate, 9-aminocamptothecin; AdPEDF.11, AE-37, albumin interferon alfa, alicaforsen sodium, alvocidib hydrochloride, AMG-706, arginine butyrate, avanafil, axitinib, azimilide hydrochloride; BAY-579352, belagenpumatucel-L, beta-lapachone, BHT-3009, BIBW-2992, bremelanotide, BX-471; Casopitant mesylate, cediranib, certolizumab pegol, CH-1504, ChimeriVax-West Nile, clofazimine, CpG-7909, curcumin, Cypher; Dapoxetine hydrochloride, darusentan, diflomotecan, D-methionine, dnaJP1, D-serine, DTPw-HB Hib-MenAC, DTPw-HepB-Hib; E-7010, ecogramostim, edodekin alfa, EGFRvlll peptide vaccine, elcometrine, elcometrine/ethinylestradiol, elsilimomab, enrasentan, ertumaxomab, etalocib sodium, exisulind; Fenretinide, fesoterodine, fingolimod hydrochloride, fontolizumab; Gefitinib, gemtuzumab ozogamicin, ghrelin (human), GV-1001; HTU-PA, human papillomavirus vaccine; Indacaterol, indiplon, interleukin-21, intranasal insulin, irinotecan hydrochloride/floxuridine, ISIS-301012, ispinesib mesylate, ixabepilone; K562/GM-CSF; Lapatinib, L-BLP-25, linezolid, liposome encapsulated paclitaxel, LY-2124275; MC-1, MC-1/lisinopril, MDX-066, melanoma vaccine, MMR-V, multivalent (ACYW) meningitis vaccine; Nilotinib, nobori, nociceptin; Oblimersen sodium, orbofiban acetate, ospemifene; Paliperidone, panitumumab, PEG-filgrastim, PEGylated interferon alfacon-1, perflubutane, pertuzumab, phenserine tartrate, phVEGF-A165, pleconaril, prasugrel, prednisolone sodium metasulfobenzoate; R-411, recombinant malaria vaccine, rhGM-CSF, roflumilast, romidepsin, ruboxistaurin mesilate hydrate; Sirolimus-eluting stent, SR-4554, St. John's Wort extract; Talabostat, Taxus, TGN-255, tifacogin, tiotropium bromide, tolevamer sodium, trabectedin, tretinoin LF; Vatalanib succinate; Yellow fever vaccine, YM-155."
|5.||Colorectal Neoplasms (Colorectal Cancer)
11/01/2007 - "The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic colorectal cancer. "
11/01/2007 - "Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer."
|7.||Measles-Mumps-Rubella Vaccine (MMR Vaccine)
|8.||Yellow Fever Vaccine (Vaccine, Yellow Fever)
|10.||Succinic Acid (Succinate)
|1.||Drug Therapy (Chemotherapy)
|2.||Vagus Nerve Stimulation
|4.||Heterologous Transplantation (Xenotransplantation)